- Home
- CNFR vs TSBX Comparison
CNFR vs TSBX Comparison
Compare CNFR & TSBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNFR
- TSBX
- Stock Information
- Founded
- CNFR 2009
- TSBX 2015
- Country
- CNFR United States
- TSBX United States
- Employees
- CNFR N/A
- TSBX N/A
- Industry
- CNFR Property-Casualty Insurers
- TSBX
- Sector
- CNFR Finance
- TSBX
- Exchange
- CNFR Nasdaq
- TSBX Nasdaq
- Market Cap
- CNFR 9.5M
- TSBX 7.7M
- IPO Year
- CNFR 2015
- TSBX 2023
- Fundamental
- Price
- CNFR $0.74
- TSBX $0.36
- Analyst Decision
- CNFR
- TSBX Buy
- Analyst Count
- CNFR 0
- TSBX 3
- Target Price
- CNFR N/A
- TSBX $4.75
- AVG Volume (30 Days)
- CNFR 5.2K
- TSBX 706.4K
- Earning Date
- CNFR 08-12-2025
- TSBX 08-13-2025
- Dividend Yield
- CNFR N/A
- TSBX N/A
- EPS Growth
- CNFR N/A
- TSBX N/A
- EPS
- CNFR 1.96
- TSBX N/A
- Revenue
- CNFR $64,021,000.00
- TSBX N/A
- Revenue This Year
- CNFR $25.91
- TSBX N/A
- Revenue Next Year
- CNFR N/A
- TSBX N/A
- P/E Ratio
- CNFR $0.38
- TSBX N/A
- Revenue Growth
- CNFR N/A
- TSBX N/A
- 52 Week Low
- CNFR $0.42
- TSBX $0.29
- 52 Week High
- CNFR $1.91
- TSBX $3.00
- Technical
- Relative Strength Index (RSI)
- CNFR 42.17
- TSBX 44.06
- Support Level
- CNFR $0.76
- TSBX $0.35
- Resistance Level
- CNFR $0.81
- TSBX $0.38
- Average True Range (ATR)
- CNFR 0.02
- TSBX 0.03
- MACD
- CNFR -0.01
- TSBX -0.00
- Stochastic Oscillator
- CNFR 1.14
- TSBX 3.67
About CNFR Conifer Holdings Inc.
Conifer Holdings Inc is an insurance holding company. The company markets and services the product offerings of the company through specialty personal insurance business lines. The company offers insurance products in Texas, Illinois, and Indiana for homeowners lines and Nevada and Michigan for other lines. The revenues of the company are derived from premiums earned from insurance operations.
About TSBX Turnstone Biologics Corp.
Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.